Indian firm that is partnering with the coronavirus vaccine development in the UK said that the vaccine trials will soon begin in India as soon as a license is procured.
The first phase trial results were published in The Lancet medical journal. It stated that the vaccine AZD1222 had a positive response and it did not have any serious side effects.
The researches added that this vaccine may have some minor side effects. However, they further added that some side effects could be removed by taking paracetamol.
Chief of the Serum Institute of India, Adar Poonawalla said that the Oxford vaccine is showing positive result and he is extremely happy about it. He is the world’s largest vaccine manufacturer. This Indian firm which is partnering the Oxford researchers. “We will be applying for the licensure trials to the Indian regulator in a week’s time. As soon as they grant us permission, we will begin with the trials for the vaccine in India. In addition, we will soon start manufacturing the vaccine in large volumes,” he added.
Moreover, India also started its first human trial of the vaccine COVAXIN. In order to arrive at the first set of data from this vaccine, it will take up to 3 years, said the AIIMS-Delhi Director Dr Randeep Guleria.
More than 100 vaccines for the coronavirus are being developed globally. Apart from the UK, China and the US are also doing clinical trials of their vaccine.
The UK government and AstraZeneca are supporting the coronavirus vaccine development by the Oxford university’s Jenner Institute.
Oxford’s vaccine is based on a version of common cold, causing infections in chimpanzees. The potential coronavirus vaccine’s name is ChAdOx1 nCoV-19. The vaccine also consists of the genetic material of the protein in the spike of SARS-CoV-2.
As per the researchers of Oxford, this vaccine can provide double immunity against the coronavirus.